152 related articles for article (PubMed ID: 26194361)
1. Carboplatin/taxane-induced gastrointestinal toxicity: a pharmacogenomics study on the SCOTROC1 trial.
He YJ; Winham SJ; Hoskins JM; Glass S; Paul J; Brown R; Motsinger-Reif A; McLeod HL
Pharmacogenomics J; 2016 Jun; 16(3):243-8. PubMed ID: 26194361
[TBL] [Abstract][Full Text] [Related]
2. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
Vasey PA; Jayson GC; Gordon A; Gabra H; Coleman R; Atkinson R; Parkin D; Paul J; Hay A; Kaye SB;
J Natl Cancer Inst; 2004 Nov; 96(22):1682-91. PubMed ID: 15547181
[TBL] [Abstract][Full Text] [Related]
3. Genetic variation of CYP3A5 influences paclitaxel/carboplatin-induced toxicity in Chinese epithelial ovarian cancer patients.
Hu L; Lv QL; Guo Y; Cheng L; Wu NY; Qin CZ; Zhou HH
J Clin Pharmacol; 2016 Mar; 56(3):349-54. PubMed ID: 26179145
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of docetaxel weekly in combination with carboplatin every 3 weeks as first-line chemotherapy in stage IIB to stage IV epithelial ovarian cancer.
Sorbe B; Graflund M; Horvath G; Swahn M; Boman K; Bangshöj R; Lood M; Malmström H
Int J Gynecol Cancer; 2012 Jan; 22(1):47-53. PubMed ID: 22193643
[TBL] [Abstract][Full Text] [Related]
5.
Li YQ; Zhang XY; Chen J; Yin JY; Li XP
J Cancer Res Ther; 2018; 14(4):881-886. PubMed ID: 29970670
[TBL] [Abstract][Full Text] [Related]
6. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
Wang Y; Herrstedt J; Havsteen H; DePoint Christensen R; Mirza MR; Lund B; Maenpaa J; Kristensen G
BMC Cancer; 2014 Dec; 14():937. PubMed ID: 25494701
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: case-control analysis of toxicity.
Hsu Y; Sood AK; Sorosky JI
Am J Clin Oncol; 2004 Feb; 27(1):14-8. PubMed ID: 14758127
[TBL] [Abstract][Full Text] [Related]
8. Role of docetaxel in the treatment of newly diagnosed advanced ovarian cancer.
Vasey PA
J Clin Oncol; 2003 May; 21(10 Suppl):136s-144s. PubMed ID: 12743129
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol.
Franca R; Rebora P; Bertorello N; Fagioli F; Conter V; Biondi A; Colombini A; Micalizzi C; Zecca M; Parasole R; Petruzziello F; Basso G; Putti MC; Locatelli F; d'Adamo P; Valsecchi MG; Decorti G; Rabusin M
Pharmacogenomics J; 2017 Jan; 17(1):4-10. PubMed ID: 26644204
[TBL] [Abstract][Full Text] [Related]
10. Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity.
McWhinney-Glass S; Winham SJ; Hertz DL; Yen Revollo J; Paul J; He Y; Brown R; Motsinger-Reif AA; McLeod HL;
Clin Cancer Res; 2013 Oct; 19(20):5769-76. PubMed ID: 23963862
[TBL] [Abstract][Full Text] [Related]
11. Feasibility study comparing docetaxel-cisplatin versus docetaxel-carboplatin as first-line chemotherapy for ovarian cancer.
Minagawa Y; Kigawa J; Kanamori Y; Itamochi H; Terakawa N; Okada M; Kitada F
Gynecol Oncol; 2006 Jun; 101(3):495-8. PubMed ID: 16375950
[TBL] [Abstract][Full Text] [Related]
12. Health-related quality of life outcomes of docetaxel/carboplatin combination therapy vs. sequential therapy with docetaxel then carboplatin in patients with relapsed, platinum-sensitive ovarian cancer: results from a randomized clinical trial.
Pokrzywinski R; Secord AA; Havrilesky LJ; Puls LE; Holloway RW; Lewandowski GS; Higgins RV; Nycum LR; Kohler MF; Revicki DA
Gynecol Oncol; 2011 Dec; 123(3):505-10. PubMed ID: 21945310
[TBL] [Abstract][Full Text] [Related]
13. Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma.
Becker DA; Thomas ED; Gilbert AL; Boone JD; Straughn JM; Huh WK; Bevis KS; Leath CA; Alvarez RD
Gynecol Oncol; 2016 Jul; 142(1):25-29. PubMed ID: 27130405
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of docetaxel weekly in combination with carboplatin every three weeks as first line chemotherapy in stage IIB-IV epithelial ovarian cancer: neurological toxicity and quality-of-life evaluation.
Sorbe B; Graflund M; Nygren L; Horvath G; Swahn M; Boman K; Bangshöj R; Lood M; Malmström H
Int J Oncol; 2012 Mar; 40(3):773-81. PubMed ID: 22159569
[TBL] [Abstract][Full Text] [Related]
15. A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer.
Alvarez Secord A; Berchuck A; Higgins RV; Nycum LR; Kohler MF; Puls LE; Holloway RW; Lewandowski GS; Valea FA; Havrilesky LJ
Cancer; 2012 Jul; 118(13):3283-93. PubMed ID: 22072307
[TBL] [Abstract][Full Text] [Related]
16. Phase II clinical trial of carboplatin and docetaxel in patients with metastatic ovarian cancer: active combination with low incidence of peripheral neuropathy.
Vorobiof DA; Rapoport BL; Chasen MR; Cohen GL; Mahomed R; Karime M
Int J Gynecol Cancer; 2003; 13(3):287-91. PubMed ID: 12801257
[TBL] [Abstract][Full Text] [Related]
17. Age-related common miRNA polymorphism associated with severe toxicity in lung cancer patients treated with platinum-based chemotherapy.
Fang C; Li XP; Gong WJ; Wu NY; Tang J; Yin JY; Li X; Zhang W; Zhou HH; Liu ZQ
Clin Exp Pharmacol Physiol; 2017 Dec; 44 Suppl 1():21-29. PubMed ID: 27873337
[TBL] [Abstract][Full Text] [Related]
18. A pilot study of docetaxel-carboplatin versus paclitaxel-carboplatin in Japanese patients with epithelial ovarian cancer.
Mori T; Hosokawa K; Kinoshita Y; Watanabe A; Yamaguchi T; Kuroboshi H; Kato Y; Yasuda J; Fujita H; Nakata Y; Honjo H
Int J Clin Oncol; 2007 Jun; 12(3):205-11. PubMed ID: 17566844
[TBL] [Abstract][Full Text] [Related]
19. Machine Learning Application Identifies Germline Markers of Hypertension in Patients With Ovarian Cancer Treated With Carboplatin, Taxane, and Bevacizumab.
Polano M; Bedon L; Dal Bo M; Sorio R; Bartoletti M; De Mattia E; Cecchin E; Pisano C; Lorusso D; Lissoni AA; De Censi A; Cecere SC; Scollo P; Marchini S; Arenare L; De Giorgi U; Califano D; Biagioli E; Chiodini P; Perrone F; Pignata S; Toffoli G
Clin Pharmacol Ther; 2023 Sep; 114(3):652-663. PubMed ID: 37243926
[TBL] [Abstract][Full Text] [Related]
20. Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial.
Nomura H; Aoki D; Michimae H; Mizuno M; Nakai H; Arai M; Sasagawa M; Ushijima K; Sugiyama T; Saito M; Tokunaga H; Matoda M; Nakanishi T; Watanabe Y; Takahashi F; Saito T; Yaegashi N;
JAMA Oncol; 2019 Jun; 5(6):833-840. PubMed ID: 30896757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
